2019 E-Poster Presenting Author Disclosures

The following types of relationships may be deemed relevant include:

1 – Shareholder
2 - Grant/Research support
3 – Employee
4 - Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)
5 - Consulting Fees (e.g., advisory boards)
6 - Officer or Board Member
7 – Royalties
8 - Speaker/Honoraria includes speakers bureau, symposia, and expert witness
9 - Other

**Pediatric E-Posters**

**Ohoud AlAhmed, MD**
*Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center*
Nothing to Disclose

**Sara Alehashemi, MD, MPH**
*Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing*
Nothing to Disclose

**Ekaterina Alexeeva**
*Long-Term Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis*
Nothing to Disclose

**Alessandra Alongi**
*Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group*
Nothing to Disclose

**Hitha Amin, MBBS, MD**
*Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?*
Nothing to Disclose

**Sheila Angeles-Han**
*Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab*
Nothing to Disclose

**Camilla Astley**
*Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial*
Nothing to Disclose

**Ugo Awa**
*Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience*
Nothing to Disclose
Daniah Basodan, MBBS. FRCPC
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Nothing to Disclose

Claudia Bracaglia
DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype
Nothing to Disclose

Claudia Bracaglia
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Monica Bray, M.D.
Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
Nothing to Disclose

AnneMarie C Brescia, MD
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Nothing to Disclose

Hermine I Brunner, MD
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Disclosures: 2- Bristol-Myers Squibb; Genentech; Pfizer; 5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB; 8-Genentech; Novartis

Hermine I Brunner, MD
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Disclosures: 2- Bristol-Myers Squibb; Genentech; Pfizer; 5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB; 8-Genentech; Novartis

Hermine I Brunner, MD
Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging
Disclosures: 2- Bristol-Myers Squibb; Genentech; Pfizer; 5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB; 8-Genentech; Novartis

Nathalie E Chalhoub
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Nothing to Disclose

Audrea Chen
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Nothing to Disclose

May Y Choi
Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
Nothing to Disclose

Adele Civino
Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study
Nothing to Disclose

Kathleen Collins, MD
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Nothing to Disclose

Ruth Costello
*Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset*
Nothing to Disclose

Fabrizio De Benedetti
*Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study*
Disclosures: 2- AbbVie; BMS; Novartis; Novartis, Novimmune, Hoffmann- La Roche, SOBI, AbbVie, Pfizer; Novimmune; Pfizer; Roche; Sanofi; Sobi; Swedish Orphan Biovitrum; UCB

Talia Diaz
*Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort*
Nothing to Disclose

Ivan Foeldvari
*Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort*
Disclosures: 5- Beyer; BMS; Glaxo; Inventa; Novartis

Ivan Foeldvari
*Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index*
Disclosures: 5- Beyer; BMS; Glaxo; Inventa; Novartis

Ivan Foeldvari
*Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort*
Disclosures: 5- Beyer; BMS; Glaxo; Inventa; Novartis

Charlene M Foley
*Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?*
Nothing to Disclose

Meghan D Foster, MSN, RN-BC, DNP Candidate 2020
*Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire*
Nothing to Disclose

Teresa Giani
*Alagille Syndrome and Chronic Arthritis: An International Case Series*
Nothing to Disclose

Mia Glerup
*Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis*
Nothing to Disclose

Sabrina Gmuca, MD MSCE
*Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome*
Nothing to Disclose

Marla Guzman, MD
*Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care*
Nothing to Disclose

Sara Haro, MD
*Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study*
Nothing to Disclose

Jonathan S Hausmann, MD
*Health--related Social Media Use by Parents of Children with Rheumatic Diseases*
Nothing to Disclose
Daniel B Horton
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Nothing to Disclose

Joyce Hui-Yuen, MD, MS
Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients
Nothing to Disclose

Joyce Hui-Yuen, MD, MS
Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)
Nothing to Disclose

Ginger Janow, MD, MPH
Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry
Nothing to Disclose

James N. Jarvis
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Nothing to Disclose

Jordan T Jones, DO, MS
The Down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Nothing to Disclose

Amelie M Jule, PhD
Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Nothing to Disclose

Ozgur Kasapcopur
Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies
Disclosure: 2-AbbVie

Ozgur Kasapcopur
Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In Turkey: A Retrospective Study, JUPITER
Disclosure: 2-AbbVie

Ozgur Kasapcopur
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Disclosure: 2-AbbVie

Young Ho Kim
Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience
Nothing to Disclose

Yukiko Kimura, MD
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices
Disclosure: 5-Novartis; Sobi

Ovgu Kul Cinar
Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Nothing to Disclose

RAKESH KUMAR
Kawasaki Disease Shock Syndrome - More Common Than We Think: Our Experience at Chandigarh, North India
Nothing to Disclose

RAKESH KUMAR
Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention

Helen J Lachmann  
*Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial*
Disclosure: 5-Novartis; Sobi

Lily SH Lim, MBBS, MRCPCH, FRCP, PhD  
*Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?*
Nothing to Disclose

S Sam Lim, MD, MPH  
*Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort*
Nothing to Disclose

Mireia Lopez-corbeto  
*Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital*
Nothing to Disclose

Anastasia-vasiliki Madenidou  
*Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients*
Nothing to Disclose

Susan M Maillard, MSc  
*Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions*
Nothing to Disclose

Melissa Mannion  
*Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry*
Nothing to Disclose

Edoardo Marrani  
*A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis*
Nothing to Disclose

Anne McHugh  
*Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthiritis and Polyarthiritis*
Nothing to Disclose

Jacob Mitchell, BSC  
*Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI*
Nothing to Disclose

Gina A Montealegre Sanchez, MD, MS  
*Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model*
Nothing to Disclose

Agna Neto  
*Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry*
Nothing to Disclose

Kate M Neufeld  
*Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus*
Nothing to Disclose

Rebecca Nicolai  
*Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis*
Nothing to Disclose
Ekemini A Ogbu, MD, MSc
Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
Nothing to Disclose
National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378 and TL1TR002382

Rebecca S Overbury, MD, MS
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Nothing to Disclose

Rebecca S Overbury, MD, MS
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Nothing to Disclose

Manuela Pardeo
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Sara T Patrizi, DO
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Nothing to Disclose

Rosemary G Peterson, MD
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Daniel Reiff
Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis
Nothing to Disclose

Jackeline Rodriguez-Smith
Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis
Nothing to Disclose

Dax G Rumsey, MD, MSc, FRCP(C)
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis Disclosure: 9- Childhood Arthritis and Rheumatology Research Alliance (CARRA)-Financial support in the form of statistical support and publication support for this study.

Rebecca E Sadun, MD, PhD
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Nothing to Disclose

Erdal Sag
Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion
Nothing to Disclose

Sujata Sawhney
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Nothing to Disclose

Sujata Sawhney
Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre
Nothing to Disclose

Christina Schutt, DO
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Nothing to Disclose
Cristina Segu-Verges
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Nothing to Disclose

Jessica Shantha, MD
Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Nothing to Disclose

Natalie Shiff
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry Disclosure: 9- CARRA (Registry Associate with salary support)

Muhammad R Shipa
Predictors of Response to Tumour Necrosis Factor - α Inhibitors (TNfi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Nothing to Disclose

Gabriele Simonini
Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry
Nothing to Disclose

Elizabeth E Sloan, MD
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Nothing to Disclose

Emily A Smitherman
Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Nothing to Disclose

Brandi Stevens, MD, MSCR
Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Nothing to Disclose

Catherine Strahle
Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients
Nothing to Disclose

Kiana Taba, MD
A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis
Nothing to Disclose

Divya Takellapti
Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation
Nothing to Disclose

Jose Luis Tandaipan
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Nothing to Disclose

Sofia Torreggiani
Multiple Genetic Diagnoses in a Cohort of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)
Nothing to Disclose

Shoko Tsuji
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS) Dislosures: 2-Chugai Pharmaceutical Co., Ltd.; Glaxo Smith Kline K.K.
Jessica L Turnier  
*Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin*  
Nothing to Disclose

Natalia Vasquez-Canizares  
*Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma*  
Nothing to Disclose

Devy Zisman, MD  
*Long-term Outcome of Juvenile-onset Psoriatic Arthritis*  
Disclosures: 5-Pfizer; 8-Pfizer

**Late-Breaking E-Posters**

Seoyoung C. Kim  
*Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study*  
AbbVie, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Merck, 2, Pfizer, 2, research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics, 2, Roche, 2, Roche/Genentech, 2

Sasha Bernatsky  
*Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity*  
Nothing to Disclose

Richard Harris  
*NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia*  
Pfizer, 1, 2, Aptinyx, 1, 2.

Maaman Bashir  
*Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease*  
Nothing to Disclose

Francesco Zulian,  
*Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma*  
Nothing to Disclose

Francesco Zulian,  
*Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients*  
Nothing to Disclose

Francesco Zulian,  
*Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis*  
Nothing to Disclose

Fabrizio De Benedetti  
*Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids*  
AbbVie, 2, BMS, 2, Novartis, 2, Novartis, Novimmune, Hoffmann- La Roche, SOBI, AbbVie, Pfizer, 2, Novimmune, 2, Pfizer, 2, Roche, 2, Sanofi, 2, Sobi, 2, Swedish Orphan Biovitrum, 2, UCB, 2

Liam O’Neil  
*A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis*  
Nothing to Disclose

Siri Lillegraven  
*Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial*  
AbbVie, 2, MSD, 2, Norwegian Research Council, 2, Norwegian South-Eastern Health Region, 2, Pfizer, 2, Roche, 2, UCB, 2
Merete Lund Hetland
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
AbbVie, 2, AbbVie, 2, Biogen, 2, BMS, 2, CellTrion, 2, 9, MSD, 2, Novartis, 2, Orion, 2, Pfizer, 2, Samsung, 2, UCB, 2

Roberta Gualtierotti
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Nothing to Disclose

Paul Emery
Maintenance of Remission Following Dose Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIb Study
AbbVie, 2, 5, 9, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, 9, Gilead, 1, Lilly, 2, 5, 9, MSD, 2, 5, 9, Novartis, 2, 5, 9, Pfizer, 2, 5, 9, Roche, 2, 5, 9, Samsung, 2, 5, 9, Samsung Bioepis Co., Ltd., 2, Sandoz, 2, 5, 9, UCB, 2, 5, 9

Mark Genovese
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
UNITY, 1

Mark Genovese
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
UNITY, 1

Philip J. Mease
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
AbbVie 2, 5, 8, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Boehringer Ingelheim 5, Celgene, 2, 5, Galapagos 5, Genentech 8, Gilead 5, GlaxoSmithKline 5, Janssen, 2, 5, 8, Lilly 2, 5, 8, Novartis 2, 5, 8, Pfizer 2, 5, 8, Sun 2, 5, UCB, 2, 5, 8

Peter Nash
Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
AbbVie, 2, 5, 8, BMS, 2, 5, 8, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 8, MSD 2, 5, 8, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8

David Isenberg
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
Genentech, Inc., 1;

Samuel Deshayes
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Nothing to Disclose

Patient Perspective E-Posters
Chisa Nosamiefan
From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving
Nothing to Disclose

Marie-Claude Beaulieu
Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team
Nothing to Disclose

Carlene Harrison
Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine
Aurinia Pharmaceuticals Inc, 5
Christele Felix
Reclaiming Medical Autonomy Through Healthcare Advocacy
Aurinia Pharmaceuticals Inc, 5

Nancy Linn
Race for Relapsing Polychondritis Drives Awareness, Accelerates Research, and Improves the Quality of My Life: How Motorsports Help Me Overcome the Hopelessness of an Incurable, Rare Disease
Nothing to Disclose

Jennifer Walker
Art for Arthritis: A New Approach
Nothing to Disclose

Debbie Schwartz
Coming to Terms with Lupus: How Learning to Listen to My Body and Letting it Tell Me What to Do Improved My Quality of Life
Nothing to Disclose

Ida Hakkarinen
Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease
Nothing to Disclose

Dalilah Kalla
Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius
Nothing to Disclose

Shannan O'Hara-Levi
The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis
Nothing to Disclose